What is Trellis Bioscience?
Trellis Bioscience is a biotechnology firm dedicated to the discovery and development of human monoclonal antibodies (mAbs) targeting infectious diseases and cancer. Their proprietary CellSpot platform is central to their product pipeline, which includes TRL1068, designed to combat challenging conditions like prosthetic joint infections and various viral infections. The company aims to provide advanced therapeutic options for healthcare providers and patients, focusing on enhancing treatment efficacy and reducing the invasiveness of medical procedures.
How much funding has Trellis Bioscience raised?
Trellis Bioscience has raised a total of $13.4M across 2 funding rounds:
Series A
$3.4M
Series B
$10M
Series A (2004): $3.4M, investors not publicly disclosed
Series B (2007): $10M, investors not publicly disclosed
What's next for Trellis Bioscience?
With this latest round of financing, Trellis Bioscience is poised to accelerate the clinical evaluation of its promising antibody candidates. The substantial backing suggests a focus on scaling operations and advancing its pipeline through key development milestones. Future strategic initiatives will likely involve further R&D investment and potential partnerships to bring their innovative treatments to market, addressing significant challenges in oncology and infectious disease therapy.
See full Trellis Bioscience company page
